Early determinants of pulmonary vascular remodeling in animal models of complex congenital heart disease

Circulation

Volumn 123, Issue 8, 2011, Pages 916-923

  Fratz, Sohrab ^a   Fineman, Jeffrey R ^a,c   Görlach, Agnes ^a   Sharma, Shruti ^d   Oishi, Peter ^a   Schreiber, Christian ^b   Kietzmann, Thomas ^e   Adatia, Ian ^f   Hess, John ^a   Black, Stephen M ^d  

^a Department of Pediatric Cardiology and Congenital Heart Disease ^*  (Germany)

^b TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d MEDICAL COLLEGE OF GEORGIA   (United States)

^e Rheinland Pfälzische Technische Universität Kaiserslautern Landau   (Germany)

^f UNIVERSITY OF ALBERTA   (Canada)

Author keywords

endothelial dysfunction; endothelin; mitochondria; nitric oxide synthase; oxidative stress

Indexed keywords

ANTIOXIDANT; ARGININE; CARNITINE; CYCLIC GMP; ENDOTHELIN 1; ENDOTHELIN A RECEPTOR; ENDOTHELIN B RECEPTOR; NITRIC OXIDE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; THROMBIN;

AMINO ACID METABOLISM; DISEASE MODEL; GENE IDENTIFICATION; HEART DISEASE; HEART MITOCHONDRION; HEART MUSCLE BLOOD FLOW; HEART MUSCLE INJURY; HEART MUSCLE ISCHEMIA; HEART SINGLE VENTRICLE; HUMAN; LUNG BLOOD FLOW; NEWBORN PERIOD; NITROSATIVE STRESS; NONHUMAN; NOTE; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PULMONARY HYPERTENSION; PULMONARY VASCULAR DISEASE; PULMONARY VASCULAR REMODELING; REPERFUSION INJURY; SIGNAL TRANSDUCTION; STROKE;

ANIMALS; HEART DEFECTS, CONGENITAL; HEART VENTRICLES; HUMANS; MODELS, ANIMAL; PULMONARY ARTERY; REGIONAL BLOOD FLOW; SHEEP; SIGNAL TRANSDUCTION;

EID: 79952382911     PISSN: 00097322     EISSN: 15244539     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.110.978528     Document Type: Note

References (65)

1. Fixler DE, Nembhard WN, Salemi JL, Ethen MK, Canfield MA. Mortality in first 5 years in infants with functional single ventricle born in Texas, 1996 to 2003. Circulation. 2010;121:644-650
2. Stumper O. Hypoplastic left heart syndrome. Heart. 2010;96:231-236
3. Reddy VM, Doff BM, Phillip M, Edwin P, Frank LH. Pulmonary artery growth after bidirectional cavopulmonary shunt: is there a cause for concern? J Thorac Cardiovasc Surg. 1996;112:1180-1192 (Pubitemid 26403415)
4. Cleuziou J, Schreiber C, Cornelsen JK, Horer J, Eicken A, Lange R. Bidirectional cavopulmonary connection without additional pulmonary blood flow in patients below the age of 6 months. Eur J Cardiothorac Surg. 2008;34:556-562
5. Hess J. Long-term problems after cavopulmonary anastomosis: diagnosis and management. Thorac Cardiovasc Surg. 2001;49:98-100 (Pubitemid 32273984)
6. Herget J. Animal models of pulmonary hypertension. Eur Respir Rev. 1993;3:559-563 (Pubitemid 24043534)
7. Reddy VM, Meyrick B, Wong J, Khoor A, Liddicoat JR, Hanley FL, Fineman JR. In utero placement of aortopulmonary shunts: a model of postnatal pulmonary hypertension with increased pulmonary blood flow in lambs. Circulation. 1995;92:1-8
8. Oishi PE, Wiseman DA, Sharma S, Kumar S, Hou Y, Datar SA, Azakie A, Johengen MJ, Harmon C, Fratz S, Fineman JR, Black SM. Progressive dysfunction of nitric oxide synthase in a lamb model of chronically increased pulmonary blood flow: a role for oxidative stress. Am J Physiol Lung Cell Mol Physiol. 2008;295:L756-L766
9. Giaid A, Saleh D. Reduced expression of endothelial nitric oxide synthase in the lungs of patients with pulmonary hypertension. N Engl J Med. 1995;333:214-221
10. Archer SL, Djaballah K, Humbert M, Weir KE, Fartoukh M, Dall'ava-Santucci J, Mercier JC, Simonneau G, Dinh-Xuan AT. Nitric oxide deficiency in fenfluramine-and dexfenfluramine-induced pulmonary hypertension. Am J Respir Crit Care Med. 1998;158:1061-1067 (Pubitemid 28489002)
11. Kiettisanpipop P, Lertsapcharorn P, Chotivittayatarakorn P, Poovorawan Y. Plasma levels of nitric oxide in children with congenital heart disease and increased pulmonary blood flow. J Med Assoc Thai. 2007;90: 2053-2057 (Pubitemid 350057099)
12. Ikemoto Y, Teraguchi M, Kobayashi Y. Plasma levels of nitrate in congenital heart disease: comparison with healthy children. Pediatr Cardiol. 2002;23:132-136 (Pubitemid 36927888)
13. Beghetti M, Silkoff PE, Caramori M, Holtby HM, Slutsky AS, Adatia I. Decreased exhaled nitric oxide may be a marker of cardiopulmonary bypass-induced injury. Ann Thorac Surg. 1998;66:532-534 (Pubitemid 28410691)
14. Hiramatsu T, Imai Y, Takanashi Y, Hoshino S, Yashima M, Tanaka SA, Chang D, Nakazawa M. Time course of endothelin-1 and nitrate anion levels after cardiopulmonary bypass in congenital heart defects. Ann Thorac Surg. 1997;63:648-652 (Pubitemid 27128673)
15. van Beynum IM, Mooij C, Kapusta L, Heil S, den Heijer M, Blom HJ. Common 894G-T single nucleotide polymorphism in the gene coding for endothelial nitric oxide synthase (eNOS) and risk of congenital heart defects. Clin Chem Lab Med. 2008;46:1369-1375
16. Godfrey V, Chan SL, Cassidy A, Butler R, Choy A, Fardon T, Struthers A, Lang C. The functional consequence of the Glu298Asp polymorphism of the endothelial nitric oxide synthase gene in young healthy volunteers. Cardiovasc Drug Rev. 2007;25:280-288 (Pubitemid 47547463)
17. Veldman BA, Spiering W, Doevendans PA, Vervoort G, Kroon AA, de Leeuw PW, Smits P. The Glu298Asp polymorphism of the NOS 3 gene as a determinant of the baseline production of nitric oxide. J Hypertens. 2002;20:2023-2027 (Pubitemid 35305500)
18. Bloch KD, Ichinose F, Roberts JD, Zapol WM. Inhaled NO as a therapeutic agent. Cardiovasc Res. 2007;75:339-348 (Pubitemid 46961928)
19. Huddleston A, Knoderer C, Morris J, Ebenroth E. Sildenafil for the treatment of pulmonary hypertension in pediatric patients. Pediatr Cardiol. 2009;30:871-882
20. Tulloh R. Etiology, diagnosis, and pharmacologic treatment of pediatric pulmonary hypertension. Paediatr Drugs. 2009;11:115-128
21. Sakurai T, Yanagisawa M, Takuwa Y, Miyazaki H, Kimura S, Goto K, Masaki T. Cloning of a cDNA encoding a non-isopeptide-selective subtype of the endothelin receptor. Nature. 1990;348:732-735 (Pubitemid 120015148)
22. Shetty SS, Okada T, Webb RL, DelGrande D, Lappe RW. Functionally distinct endothelin B receptors in vascular endothelium and smooth muscle. Biochem Biophys Res Commun. 1993;191:459-464 (Pubitemid 23222658)
23. Bradley LM, Czaja JF, Goldstein RE. Circulatory effects of endothelin in newborn piglets. Am J Physiol. 1990;259:H1613-H1617 (Pubitemid 20385767)
24. Cassin S, Kristova V, Davis T, Kadowitz P, Gause G. Tone-dependent responses to endothelin in isolated perfused fetal sheep pulmonary circulation in situ. J Appl Physiol. 1991;70:1228-1234
25. Hell JW, Yokoyama CT, Wong ST, Warner C, Snutch TP, Catterall WA. Differential phosphorylation of two size forms of the neuronal class C L-type calcium channel alpha 1 subunit. J Biol Chem. 1993;268: 19451-19457 (Pubitemid 23270725)
26. Arai H, Hori S, Aramori I, Ohkubo H, Nakanishi S. Cloning and expression of a cDNA encoding an endothelin receptor. Nature. 1990; 348:730-732 (Pubitemid 120015147)
27. Wedgwood S, Dettman R, Black S. ET-1 stimulates pulmonary arterial smooth muscle cell proliferation via induction of reactive oxygen species. Am J Physiol. 2001;281:L1058-L1067
28. Giaid A, Michel RP, Stewart DJ, Sheppard M, Corrin B, Hamid Q. Expression of endothelin-1 in lungs of patients with cryptogenic fibrosing alveolitis. Lancet. 1993;341:1550-1554 (Pubitemid 23170459)
29. Fratz S, Geiger R, Kresse H, Roemer G, Hennig M, Sebening W, Hess J. Pulmonary blood pressure, not flow, is associated with net endothelin-1 production in the lungs of patients with congenital heart disease and normal pulmonary vascular resistance. J Thorac Cardiovasc Surg. 2003; 126:1724-1729 (Pubitemid 38020726)
30. Gorenflo M, Gross P, Bodey A, Schmitz L, Brockmeier K, Berger F, Bein G, Lange PE. Plasma endothelin-1 in patients with left-to-right shunt. Am Heart J. 1995;130:537-542
31. Beghetti M. Current treatment options in children with pulmonary arterial hypertension and experiences with oral bosentan. Eur J Clin Invest. 2006;36:16-24 (Pubitemid 44179777)
32. Nisbet RE, Sutliff RL, Hart CM. The role of peroxisome proliferator-activated receptors in pulmonary vascular disease. PPAR Res. 2007;2007: 18797
33. Hansmann G, de Jesus Perez VA, Alastalo T-P, Alvira CM, Guignabert C, Bekker JM, Schellong S, Urashima T, Wang L, Morrell NW, Rabinovitch M. An antiproliferative BMP-2/PPARgamma/apoE axis in human and murine SMCs and its role in pulmonary hypertension. J Clin Invest. 2008;118:1846-1857 (Pubitemid 351632387)
34. Hansmann G, Wagner RA, Schellong S, de Jesus Perez VA, Urashima T, Wang L, Sheikh AY, Suen RS, Stewart DJ, Rabinovitch M. Pulmonary arterial hypertension is linked to insulin resistance and reversed by peroxisome proliferator-activated receptor-activation. Circulation. 2007; 115:1275-1284 (Pubitemid 46594772)
35. Tian J, Smith A, Nechtman J, Podolsky R, Aggarwal S, Snead C, Kumar S, Elgaish M, Oishi P, Goerlach A, Fratz S, Hess J, Catravas JD, Verin AD, Fineman JR, She JX, Black SM. Effect of PPARgamma inhibition on pulmonary endothelial cell gene expression: gene profiling in pulmonary hypertension. Physiol Genomics. 2009;40:48-60
36. Sharma S, Kumar S, Sud N, Wiseman DA, Tian J, Rehmani I, Datar S, Oishi P, Fratz S, Venema RC, Fineman JR, Black SM. Alterations in lung arginine metabolism in lambs with pulmonary hypertension associated with increased pulmonary blood flow. Vascul Pharmacol. 2009;51: 359-364
37. Howell K, Costello CM, Sands M, Dooley I, McLoughlin P. L-Arginine promotes angiogenesis in the chronically hypoxic lung: a novel mechanism ameliorating pulmonary hypertension. Am J Physiol Lung Cell Mol Physiol. 2009;296:L1042-L1050
38. Harrison DG, Gongora MC. Oxidative stress and hypertension. Med Clin North Am. 2009;93:621-635
39. Grobe AC, Wells SM, Benavidez E, Oishi P, Azakie A, Fineman JR, Black SM. Increased oxidative stress in lambs with increased pulmonary blood flow and pulmonary hypertension: role of NADPH oxidase and endothelial NO synthase. Am J Physiol Lung Cell Mol Physiol. 2006; 290:L1069-L1077 (Pubitemid 43830850)
40. Sharma S, Grobe AC, Wiseman DA, Kumar S, Englaish M, Najwer I, Benavidez E, Oishi P, Azakie A, Fineman JR, Black SM. Lung antioxidant enzymes are regulated by development and increased pulmonary blood flow. Am J Physiol Lung Cell Mol Physiol. 2007;293:L960-L971 (Pubitemid 47572244)
41. Sharma S, Kumar S, Wiseman DA, Kallarackal S, Ponnala S, Elgaish M, Tian J, Fineman JR, Black SM. Perinatal changes in superoxide generation in the ovine lung: alterations associated with increased pulmonary blood flow. Vascul Pharmacol. 2010;53:38-52
42. Sud N, Sharma S, Wiseman DA, Harmon C, Kumar S, Venema RC, Fineman JR, Black SM. Nitric oxide and superoxide generation from endothelial NOS: modulation by HSP90. Am J Physiol Lung Cell Mol Physiol. 2007;293:L1444-L1453 (Pubitemid 350255027)
43. Diebold I, Petry A, Djordjevic T, BelAiba RS, Fineman JR, Black SM, Schreiber C, Fratz S, Hess J, Kietzmann T, Gorlach A. Reciprocal regulation of Rac1 and PAK-1 by HIF-1-: a positive-feedback loop promoting pulmonary vascular remodeling. Antioxid Redox Signal. 2010; 13:399-412
44. Calabrese V, Cornelius C, Rizzarelli E, Owen JB, Dinkova-Kostova AT, Butterfield DA. Nitric oxide in cell survival: a Janus molecule. Antioxid Redox Signal. 2009;11:2717-2739
45. Zickus M, Fonseca FV, Tummala M, Black SM, Ryzhov V. Identification of the tyrosine nitration sites in human endothelial nitric oxide synthase by liquid chromatography-mass spectrometry. Eur J Mass Spectrom. 2008;14:239-247
46. Djordjevic T, Hess J, Herkert O, Gorlach A, BelAiba RS. Rac regulates thrombin-induced tissue factor expression in pulmonary artery smooth muscle cells involving the nuclear factor-kappaB pathway. Antioxid Redox Signal. 2004;6:713-720 (Pubitemid 38890788)
47. Bonello S, Zahringer C, BelAiba RS, Djordjevic T, Hess J, Michiels C, Kietzmann T, Gorlach A. Reactive oxygen species activate the HIF-1-promoter via a functional NF-B site. Arterioscler Thromb Vasc Biol. 2007;27:755-761 (Pubitemid 46606703)
48. BelAiba RS, Djordjevic T, Bonello S, Artunc F, Lang F, Hess J, Gorlach A. The serum-and glucocorticoid-inducible kinase Sgk-1 is involved in pulmonary vascular remodeling: role in redox-sensitive regulation of tissue factor by thrombin. Circ Res. 2006;98:828-836
49. Sharma S, Sud N, Wiseman DA, Carter AL, Kumar S, Hou Y, Rau T, Wilham J, Harmon C, Oishi P, Fineman JR, Black SM. Altered carnitine homeostasis is associated with decreased mitochondrial function and altered nitric oxide signaling in lambs with pulmonary hypertension. Am J Physiol Lung Cell Mol Physiol. 2008;294:L46-L56 (Pubitemid 351380317)
50. Archer SL, Marsboom G, Kim GH, Zhang HJ, Toth PT, Svensson EC, Dyck JR, Gomberg-Maitland M, Thebaud B, Husain AN, Cipriani N, Rehman J. Epigenetic attenuation of mitochondrial superoxide dismutase 2 in pulmonary arterial hypertension: a basis for excessive cell proliferation and a new therapeutic target. Circulation. 2010;121:2661-2671
51. Davidson SM. Endothelial mitochondria and heart disease. Cardiovasc Res. 2010;88:58-66
52. Cheng X, Siow RC, Mann GE. Impaired redox signaling and antioxidant gene expression in endothelial cells in diabetes: a role for mitochondria and the Nrf2-Keap1 defense pathway. Antioxid Redox Signal. 2011;14: 469-487
53. Leduc L, Levy E, Bouity-Voubou M, Delvin E. Fetal programming of atherosclerosis: possible role of the mitochondria. Eur J Obstet Gynecol Reprod Biol. 2010;149:127-130
54. Graham D, Huynh NN, Hamilton CA, Beattie E, Smith RA, Cocheme HM, Murphy MP, Dominiczak AF. Mitochondria-targeted antioxidant MitoQ10 improves endothelial function and attenuates cardiac hypertrophy. Hypertension. 2009;54:322-328
55. Supinski GS, Murphy MP, Callahan LA. MitoQ administration prevents endotoxin-induced cardiac dysfunction. Am J Physiol Regul Integr Comp Physiol. 2009;297:R1095-R1102
56. Adlam VJ, Harrison JC, Porteous CM, James AM, Smith RA, Murphy MP, Sammut IA. Targeting an antioxidant to mitochondria decreases cardiac ischemia-reperfusion injury. FASEB J. 2005;19:1088-1095 (Pubitemid 40946434)
57. Rocha M, Esplugues JV, Hernandez-Mijares A, Victor VM. Mitochondrial-targeted antioxidants and oxidative stress: a proteomic prospective study. Curr Pharm Des. 2009;15:3052-3062
58. Armstrong JS. Mitochondria-directed therapeutics. Antioxid Redox Signal. 2008;10:575-578
59. Konduri GG, Mital S. Adenosine and ATP cause nitric oxide-dependent pulmonary vasodilation in fetal lambs. Biol Neonate. 2000;78:220-229
60. Garcia-Cardena G, Fan R, Shah V, Sorrentino R, Cirino G, Papapetropoulos A, Sessa WC. Dynamic activation of endothelial nitric oxide synthase by Hsp90. Nature. 1998;392:821-824 (Pubitemid 28225323)
61. Pritchard K, Stepp D, Konduri G. Inhibition of heatshock protein 90 activity impairs vasorelaxation by increasing superoxide anion generation by endothelial nitric oxide synthase (eNOS). Circulation. 2001;104:500. Abstract
62. Sud N, Wells SM, Sharma S, Wiseman DA, Wilham J, Black SM. Asymmetric dimethylarginine inhibits HSP90 activity in pulmonary arterial endothelial cells: role of mitochondrial dysfunction. Am J Physiol Cell Physiol. 2008;294:C1407-C1418
63. Arrigoni FI, Vallance P, Haworth SG, Leiper JM. Metabolism of asymmetric dimethylarginines is regulated in the lung developmentally and with pulmonary hypertension induced by hypobaric hypoxia. Circulation. 2003;107:1195-1201 (Pubitemid 36297214)
64. Millatt LJ, Whitley GS, Li D, Leiper JM, Siragy HM, Carey RM, Johns RA. Evidence for dysregulation of dimethylarginine dimethylaminohydrolase I in chronic hypoxia-induced pulmonary hypertension. Circulation. 2003;108:1493-1498 (Pubitemid 37176457)
65. Gorenflo M, Zheng C, Pöge A, Bettendorf M, Werle E, Fiehn W, Ulmer H. Metabolites of the L-arginine-NO pathway in patients with left-to-right shunt. Clin Lab. 2001;47:441-447 (Pubitemid 32927024)